Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)
Articles > Article · 2013
Authors: Fikri Icli, Kadri Altundag, Hakan Akbulut, SEMRA PAYDAŞ, Gul Basaran, Pinar Saip, Gamze G. Dogu, Yesim Erlap, RÜÇHAN USLU, Alper Sevinc, Handan Onur, Nil M. Mandel, Canfeza Sezgin, Mustafa Altinbas, Nilufer Guler, Abdurrahman Isikdogan, Erhan GÖKMEN, Kazim Uygun, Zeki Ustuner, Arzu Yaren, Binnaz Demirkan, Ugur Coskun, Alper Ata, Metin Ozkan, Ali Arican
Breast Cancer, Journal Indexed in SCI Expanded, International, WoS, 2013, vol 22, pp 480-485
DOI: 10.1007/s12282-013-0506-y
Summary
Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.